IL13RA2 and renal cell carcinoma: The IL13Rα2-positivity had a 2.627-fold (95% CI; 1.132–6.097) greater risk of death and a 2.801-fold (95% CI; 1.3795.688) greater risk of relapse or death of RCC patients (Table 3).